JP5714228B2 - ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形 - Google Patents

３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形 Download PDF

Info

Publication number
JP5714228B2
JP5714228B2 JP2009529270A JP2009529270A JP5714228B2 JP 5714228 B2 JP5714228 B2 JP 5714228B2 JP 2009529270 A JP2009529270 A JP 2009529270A JP 2009529270 A JP2009529270 A JP 2009529270A JP 5714228 B2 JP5714228 B2 JP 5714228B2
Authority
JP
Japan
Prior art keywords
disease
cancer
fluorophenyl
benzoic acid
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009529270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504340A (ja
JP2010504340A5 (enExample
Inventor
ジー．アルムステアド ネイル
ジー．アルムステアド ネイル
セオングウォオ フワング ペテル
セオングウォオ フワング ペテル
モオン ヨウング‐チョオン
モオン ヨウング‐チョオン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39123850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5714228(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of JP2010504340A publication Critical patent/JP2010504340A/ja
Publication of JP2010504340A5 publication Critical patent/JP2010504340A5/ja
Application granted granted Critical
Publication of JP5714228B2 publication Critical patent/JP5714228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
JP2009529270A 2006-09-25 2007-09-24 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形 Active JP5714228B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84732606P 2006-09-25 2006-09-25
US60/847,326 2006-09-25
PCT/US2007/020633 WO2008039431A2 (en) 2006-09-25 2007-09-24 Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015003265A Division JP6407733B2 (ja) 2006-09-25 2015-01-09 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形

Publications (3)

Publication Number Publication Date
JP2010504340A JP2010504340A (ja) 2010-02-12
JP2010504340A5 JP2010504340A5 (enExample) 2010-11-11
JP5714228B2 true JP5714228B2 (ja) 2015-05-07

Family

ID=39123850

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2009529270A Active JP5714228B2 (ja) 2006-09-25 2007-09-24 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
JP2015003265A Active JP6407733B2 (ja) 2006-09-25 2015-01-09 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
JP2017106030A Active JP6495375B2 (ja) 2006-09-25 2017-05-29 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
JP2019040137A Withdrawn JP2019104752A (ja) 2006-09-25 2019-03-06 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
JP2021090763A Active JP7245868B2 (ja) 2006-09-25 2021-05-31 ３－［５－（２－フルオロフェニル）－［１，２，４］オキサジアゾール－３－イル］－安息香酸の結晶形
JP2023038770A Pending JP2023078271A (ja) 2006-09-25 2023-03-13 ３－［５－（２－フルオロフェニル）－［１，２，４］オキサジアゾール－３－イル］－安息香酸の結晶形

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015003265A Active JP6407733B2 (ja) 2006-09-25 2015-01-09 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
JP2017106030A Active JP6495375B2 (ja) 2006-09-25 2017-05-29 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
JP2019040137A Withdrawn JP2019104752A (ja) 2006-09-25 2019-03-06 ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
JP2021090763A Active JP7245868B2 (ja) 2006-09-25 2021-05-31 ３－［５－（２－フルオロフェニル）－［１，２，４］オキサジアゾール－３－イル］－安息香酸の結晶形
JP2023038770A Pending JP2023078271A (ja) 2006-09-25 2023-03-13 ３－［５－（２－フルオロフェニル）－［１，２，４］オキサジアゾール－３－イル］－安息香酸の結晶形

Country Status (29)

Country Link
US (10) US7863456B2 (enExample)
EP (2) EP2559689B1 (enExample)
JP (6) JP5714228B2 (enExample)
KR (1) KR101430144B1 (enExample)
CN (3) CN104341371A (enExample)
AR (2) AR062963A1 (enExample)
AU (1) AU2007300542B2 (enExample)
BR (1) BRPI0717107A2 (enExample)
CA (1) CA2663574C (enExample)
CL (1) CL2007002743A1 (enExample)
DK (1) DK2076501T3 (enExample)
ES (2) ES2563958T3 (enExample)
HK (1) HK1207070A1 (enExample)
HU (1) HUE028503T2 (enExample)
IL (1) IL197717A (enExample)
LT (1) LTC2076501I2 (enExample)
MX (2) MX2009003160A (enExample)
MY (1) MY191209A (enExample)
NO (1) NO341858B1 (enExample)
NZ (1) NZ575795A (enExample)
PE (3) PE20081225A1 (enExample)
PL (2) PL2559689T3 (enExample)
PT (1) PT2076501E (enExample)
SG (2) SG10201609581TA (enExample)
SI (1) SI2076501T1 (enExample)
TW (2) TWI452038B (enExample)
UA (1) UA99600C2 (enExample)
WO (1) WO2008039431A2 (enExample)
ZA (1) ZA200901949B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015110607A (ja) * 2006-09-25 2015-06-18 ピーティーシー セラピューティクス，インコーポレーテッド ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
AU2006235115C1 (en) * 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
EP2387995A1 (en) * 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
KR20170100072A (ko) 2006-10-12 2017-09-01 피티씨 테라퓨틱스, 인크. 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
WO2014153643A1 (en) * 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
US9347014B2 (en) 2013-04-03 2016-05-24 Gfo Oil Llc Methods and systems for generating aldehydes from organic seed oils
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
KR101703137B1 (ko) 2014-05-30 2017-02-07 선문대학교 산학협력단 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
TW201729807A (zh) 2015-10-30 2017-09-01 Ｐｔｃ治療公司 用於治療癲癇的方法
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
EP3512516A1 (en) * 2016-09-13 2019-07-24 Marco Cipolli Method of treatment of shwachman-diamond syndrome
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
AU2018348350B2 (en) 2017-10-11 2024-05-02 Aurigene Oncology Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2020004531A (es) 2017-11-03 2020-08-03 Aurigene Discovery Tech Ltd Inhibidores dobles de tim-3 y las vias de pd-1.
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
KR20210151131A (ko) 2019-04-10 2021-12-13 피티씨 테라퓨틱스, 인크. 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법
JP7339900B2 (ja) * 2020-02-26 2023-09-06 新 井上 視野異常診断方法、視野異常診断装置
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
WO2025110781A1 (ko) * 2023-11-24 2025-05-30 재단법인 아산사회복지재단 Ampd3를 포함하는 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 ampd3 저해제를 포함하는 신경섬유종증 예방 또는 치료용 약학 조성물
CN118178408A (zh) * 2024-03-22 2024-06-14 核工业总医院 Ptc124在制备治疗血小板无力症的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW264475B (enExample) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7041685B2 (en) * 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US6889231B1 (en) * 2002-08-01 2005-05-03 Oracle International Corporation Asynchronous information sharing system
CN1691944A (zh) * 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的噁二唑
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP4101846B1 (en) * 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) * 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
JP2008515992A (ja) * 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用
US20100130500A1 (en) * 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
AU2006235115C1 (en) * 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
NZ598012A (en) * 2006-09-08 2013-08-30 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids
UA99600C2 (en) * 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015110607A (ja) * 2006-09-25 2015-06-18 ピーティーシー セラピューティクス，インコーポレーテッド ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形

Also Published As

Publication number Publication date
KR20090057457A (ko) 2009-06-05
US20210330647A1 (en) 2021-10-28
CL2007002743A1 (es) 2008-07-11
ES2563958T3 (es) 2016-03-16
US20130158081A1 (en) 2013-06-20
TW201420578A (zh) 2014-06-01
SG185979A1 (en) 2012-12-28
NO20091488L (no) 2009-06-17
AR062963A1 (es) 2008-12-17
HK1207070A1 (en) 2016-01-22
SG10201609581TA (en) 2016-12-29
LTC2076501I2 (lt) 2017-10-10
AU2007300542A1 (en) 2008-04-03
PE20120768A1 (es) 2012-06-27
US20220023268A1 (en) 2022-01-27
PL2559689T3 (pl) 2018-04-30
TWI452038B (zh) 2014-09-11
JP2010504340A (ja) 2010-02-12
US10300047B2 (en) 2019-05-28
BRPI0717107A2 (pt) 2013-10-15
JP7245868B2 (ja) 2023-03-24
US7863456B2 (en) 2011-01-04
NO341858B1 (no) 2018-02-12
CN102382075A (zh) 2012-03-21
AR109300A2 (es) 2018-11-14
WO2008039431A2 (en) 2008-04-03
JP2023078271A (ja) 2023-06-06
US10959988B2 (en) 2021-03-30
US10028939B2 (en) 2018-07-24
WO2008039431A3 (en) 2008-05-08
ZA200901949B (en) 2010-07-28
JP2021130697A (ja) 2021-09-09
CN101541770A (zh) 2009-09-23
CN104341371A (zh) 2015-02-11
US20080171377A1 (en) 2008-07-17
PL2076501T3 (pl) 2016-06-30
RU2009115649A (ru) 2010-11-10
US20200330440A1 (en) 2020-10-22
JP2017160253A (ja) 2017-09-14
CN102382075B (zh) 2015-10-28
NZ575795A (en) 2012-03-30
EP2076501A2 (en) 2009-07-08
US9309206B2 (en) 2016-04-12
JP6407733B2 (ja) 2018-10-17
WO2008039431B1 (en) 2008-07-10
SI2076501T1 (sl) 2016-05-31
EP2076501B8 (en) 2019-11-13
JP2019104752A (ja) 2019-06-27
US8394966B2 (en) 2013-03-12
HUE028503T2 (en) 2016-12-28
PE20151445A1 (es) 2015-09-28
EP2076501B1 (en) 2015-12-02
JP6495375B2 (ja) 2019-04-03
CA2663574A1 (en) 2008-04-03
IL197717A0 (en) 2009-12-24
US20140235679A1 (en) 2014-08-21
US20110040100A1 (en) 2011-02-17
MX344418B (es) 2016-12-15
CA2663574C (en) 2015-11-24
US20180296538A1 (en) 2018-10-18
EP2559689B1 (en) 2017-11-29
MY191209A (en) 2022-06-08
PE20081225A1 (es) 2008-09-04
RU2474577C2 (ru) 2013-02-10
EP2559689A1 (en) 2013-02-20
PT2076501E (pt) 2016-03-31
KR101430144B1 (ko) 2014-08-13
UA99600C2 (en) 2012-09-10
DK2076501T3 (da) 2016-02-29
MX2009003160A (es) 2009-04-06
US20190231754A1 (en) 2019-08-01
US8748625B2 (en) 2014-06-10
IL197717A (en) 2015-06-30
TW200823181A (en) 2008-06-01
TWI496775B (zh) 2015-08-21
AU2007300542B2 (en) 2012-05-17
ES2655338T3 (es) 2018-02-19
JP2015110607A (ja) 2015-06-18
US20160193189A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
JP7245868B2 (ja) ３－［５－（２－フルオロフェニル）－［１，２，４］オキサジアゾール－３－イル］－安息香酸の結晶形
HK1181043A (en) Preparation process for crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid
HK1168354A (en) Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
HK1168354B (en) Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
HK1134292A (en) Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150311

R150 Certificate of patent or registration of utility model

Ref document number: 5714228

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250